An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer

Onkologie

Volumn 30, Issue 7, 2007, Pages 355-360

  Salzberg, M ^a   Rochlitz, C ^a   Morant, R ^b   Thalmann, G ^c   Pedrazzini, A ^d   Roggero, E ^d   Schonenberger A ^e   Knuth, A ^f   Borner, M ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Tumor Center ZeTuP   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d Clinica Santa Chiara   (Switzerland)

^e CANTONAL HOSPITAL AARAU   (Switzerland)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Docetaxel; EGFR inhibition; Gefitinib; Prostate cancer

Indexed keywords

DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; GEFITINIB; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANOREXIA; ARTICLE; BURSITIS; CANCER HORMONE THERAPY; CHEMOTHERAPY INDUCED EMESIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DUODENUM ULCER; DYSGEUSIA; FATIGUE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DISEASE; MALE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; SIDE EFFECT; SKIN ABSCESS; STOMATITIS; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUINAZOLINES; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 34347335625     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102452     Document Type: Article

References (22)

1. Sherwood ER, Van Dongen JL, Wood CG, Liao S, Kozlowski JM, Lee C: Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer 1998;77:855-861.
2. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-250.
3. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
4. Wosikowski K, Silverman JA, Bishop P, Mendelsohn J, Bates SE: Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells. Biochim Biophys Acta 2000;1497:215-226.
5. Torring N, Jorgensen PE, Sorensen BS, Nexo E: Increased expression of heparin binding EGF (HBEGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res 2000;20:91-95.
6. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones PA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
7. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
8. Hainsworth JD, Burris HA 3rd, Greco FA: Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancer. Semin Oncol 2001;28(suppl 9):21-25.
9. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED: Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006;98: 516-521.
10. Gilbert DC, Parker DC: Docetaxel for the treatment of prostate cancer. Future Oncol 2005;1: 307-314.
11. Sordella R, Bell DW, Haber DA, Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305: 1163-1167.
12. Wilding G, Soulie P, Trump D, Das-Gupta A, Small E: Results from a pilot phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Cancer 2006;106:1917-1924.
13. Riedel RF, Febbo PG: Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. Future Oncol 2005;1:461-466.
14. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, Van Groeningen C, Giaccone G: Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006;24:1612-1619.
15. Herbst RS, Kies MS: Gefitinib: current and future status in cancer therapy. Clin Adv Hematol Oncol 2003;1:466-472.
16. Sirotnak FM: Studies with ZD1839 in preclinical models. Semin Oncol 2003;30(suppl 1):12-20.
17. Von Pawel J: Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors. Bull Cancer 2004;91:E70-76.
18. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004;22:777-784.
19. Herbst RS, Giaccone G, Schiller JH: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004;22:785-794.
20. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966.
21. Lee DH, Han JY, Kim HT, Lee JS: Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients. Lung Cancer 2006;53:339-345.
22. Engelman JA, Janne PA: Factors predicting response to EGFR tyrosine kinase inhibitors. Semin Respir Crit Care Med 2005;26:314-322.